SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]
SEC Accession No. 0001493152-23-014979
Filing Date
2023-05-01
Accepted
2023-05-01 16:47:11
Documents
14
Period of Report
2022-12-31

Document Format Files

Seq Description Document Type Size
1 form10-ka.htm   iXBRL 10-K/A 379835
2 ex31-3.htm EX-31.3 3962
3 ex31-4.htm EX-31.4 4114
  Complete submission text file 0001493152-23-014979.txt   649806

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT ocx-20221231.xsd EX-101.SCH 3224
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT ocx-20221231_lab.xml EX-101.LAB 36257
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT ocx-20221231_pre.xml EX-101.PRE 23745
8 EXTRACTED XBRL INSTANCE DOCUMENT form10-ka_htm.xml XML 6037
Mailing Address 15 CUSHING IRVINE CA 92618
Business Address 15 CUSHING IRVINE CA 92618 949-409-7600
Oncocyte Corp (Filer) CIK: 0001642380 (see all company filings)

IRS No.: 271041563 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-K/A | Act: 34 | File No.: 001-37648 | Film No.: 23874518
SIC: 2835 In Vitro & In Vivo Diagnostic Substances